Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Zanubrutinib (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
Most Recent Events
- 11 Jun 2024 New trial record